{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T04:19:25Z","timestamp":1788322765644,"version":"build-2803163510"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T00:00:00Z","timestamp":1629763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T00:00:00Z","timestamp":1629763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Ningxia Key R&D Program (Social Development Field) Key Project","award":["2018BEG02002"],"award-info":[{"award-number":["2018BEG02002"]}]},{"name":"Discipline Construction Project of Guangdong Medical University","award":["4SG21278P"],"award-info":[{"award-number":["4SG21278P"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Taking advantage of nanobodies (Nbs) in immunotherapy, we investigated the cytotoxicity of Nb-based chimeric antigen receptor T cells (Nb CAR-T) against lymphoma cells.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>CD19 Nb CAR-T, CD20 Nb CAR-T, and Bispecific Nb CAR-T cells were generated by panning anti-human CD19- and CD20-specific nanobody sequences from a natural Nb-expressing phage display library, integrating Nb genes with a lentiviral cassette that included other CAR elements, and finally transducing T cells that were expanded under an optimization system with the above generated CAR lentivirus. Prepared Nb CAR-T cells were cocultured with tumour cell lines or primary tumour cells for 24\u00a0h or 5 days to evaluate their biological function.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The nanobodies that we selected from the natural Nb-expressing phage display library had a high affinity and specificity for CD19 and CD20. CD19 Nb CAR-T, CD20 Nb CAR-T and Bispecific\u00a0Nb CAR-T cells were successfully constructed, and these Nb CAR-T cells could strongly recognize Burkitt lymphoma cell lines (Raji and Daudi), thereby leading to activation, enhanced proliferation, and specific killing of target cells. Furthermore, similar results were obtained when using patient samples as target cells, with a cytotoxicity of approximately 60%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Nanobody-based CAR-T cells can kill both tumour cell lines and patient-derived tumour cells in vitro, and Nb-based CAR-T cells may be a promising therapeutic strategy in future immunotherapy.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s12935-021-02151-z","type":"journal-article","created":{"date-parts":[[2021,8,24]],"date-time":"2021-08-24T12:03:03Z","timestamp":1629806583000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Nanobody-armed T cells endow CAR-T cells with cytotoxicity against lymphoma cells"],"prefix":"10.1186","volume":"21","author":[{"given":"Hongxia","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuankui","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0481-9625","authenticated-orcid":false,"given":"Guangxian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,24]]},"reference":[{"key":"2151_CR1","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","volume":"36","author":"R Grosser","year":"2019","unstructured":"Grosser R, Cherkassky L, Chintala N, et al. Combination immunotherapy with CAR T cells and checkpoint blockade for the treatment of solid tumors. Cancer cell. 2019;36:471\u201382.","journal-title":"Cancer cell"},{"key":"2151_CR2","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/s41422-020-0343-4","volume":"30","author":"X He","year":"2020","unstructured":"He X, Xu C. Immune checkpoint signaling and cancer immunotherapy. Cell Res. 2020;30:660\u20139.","journal-title":"Cell Res"},{"key":"2151_CR3","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/S0140-6736(20)32598-8","volume":"397","author":"F Meric-Bernstam","year":"2021","unstructured":"Meric-Bernstam F, Larkin J, Tabernero J, et al. Enhancing anti-tumour efficacy with immunotherapy combinations. Lancet. 2021;397:1010\u201322.","journal-title":"Lancet"},{"key":"2151_CR4","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"A Waldman","year":"2020","unstructured":"Waldman A, Fritz J, Lenardo M. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat Rev Immunol. 2020;20:651\u201368.","journal-title":"Nat Rev Immunol"},{"key":"2151_CR5","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.cell.2020.03.001","volume":"181","author":"E Weber","year":"2020","unstructured":"Weber E, Maus M, Mackall C. The emerging landscape of immune cell therapies. Cell. 2020;181:46\u201362.","journal-title":"Cell"},{"key":"2151_CR6","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1158\/2159-8290.CD-20-1209","volume":"11","author":"T Yap","year":"2021","unstructured":"Yap T, Parkes E, Peng W, et al. Development of immunotherapy combination strategies in cancer. Cancer Discov. 2021;11:1368\u201397.","journal-title":"Cancer Discov"},{"key":"2151_CR7","doi-asserted-by":"publisher","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","volume":"377","author":"S Neelapu","year":"2017","unstructured":"Neelapu S, Locke F, Bartlett N, et al. Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-Cell lymphoma. N Engl J Med. 2017;377:2531\u201344.","journal-title":"N Engl J Med."},{"key":"2151_CR8","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"N Munshi","year":"2021","unstructured":"Munshi N, Anderson L, Shah N, et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021;384:705\u201316.","journal-title":"N Engl J Med"},{"key":"2151_CR9","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/CJI.0000000000000307","volume":"43","author":"J Qin","year":"2020","unstructured":"Qin J, Johnstone T, Baturevych A, et al. Antitumor potency of an anti-CD19 chimeric antigen receptor T-cell therapy, lisocabtagene maraleucel in combination with ibrutinib or acalabrutinib. J Immunother. 2020;43:107\u201320.","journal-title":"J Immunother"},{"key":"2151_CR10","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/nbt0817-691","volume":"35","author":"C Sheridan","year":"2017","unstructured":"Sheridan C. First approval in sight for Novartis\u2019 CAR-T therapy after panel vote. Nat Biotechnol. 2017;35:691\u20133.","journal-title":"Nat Biotechnol"},{"key":"2151_CR11","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382:1331\u201342.","journal-title":"N Engl J Med"},{"key":"2151_CR12","doi-asserted-by":"publisher","first-page":"104","DOI":"10.4049\/jimmunol.172.1.104","volume":"172","author":"H Finney","year":"2004","unstructured":"Finney H, Akbar A, Lawson A. Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol. 2004;172:104\u201313.","journal-title":"J Immunol"},{"key":"2151_CR13","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/0092-8674(91)90314-O","volume":"64","author":"B Irving","year":"1991","unstructured":"Irving B, Weiss A. The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways. Cell. 1991;64:891\u2013901.","journal-title":"Cell"},{"key":"2151_CR14","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","volume":"3","author":"M Sadelain","year":"2013","unstructured":"Sadelain M, Brentjens R, Rivi\u00e8re I. The basic principles of chimeric antigen receptor design. Cancer Discov. 2013;3:388\u201398.","journal-title":"Cancer Discov"},{"key":"2151_CR15","doi-asserted-by":"publisher","first-page":"10024","DOI":"10.1073\/pnas.86.24.10024","volume":"86","author":"G Gross","year":"1989","unstructured":"Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci U S A. 1989;86:10024\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2151_CR16","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/0006-291X(87)90502-X","volume":"149","author":"Y Kuwana","year":"1987","unstructured":"Kuwana Y, Asakura Y, Utsunomiya N, et al. Expression of chimeric receptor composed of immunoglobulin-derived V regions and T-cell receptor-derived C regions. Biochem Biophys Res Commun. 1987;149:960\u20138.","journal-title":"Biochem Biophys Res Commun"},{"key":"2151_CR17","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/nri1837","volume":"6","author":"P Carter","year":"2006","unstructured":"Carter P. Potent antibody therapeutics by design. Nat Rev Immunol. 2006;6:343\u201357.","journal-title":"Nat Rev Immunol"},{"key":"2151_CR18","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s40259-019-00354-5","volume":"33","author":"B Gorovits","year":"2019","unstructured":"Gorovits B, Koren E. Immunogenicity of chimeric antigen receptor T-cell therapeutics. BioDrugs. 2019;33:275\u201384.","journal-title":"BioDrugs"},{"key":"2151_CR19","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.omtm.2018.12.009","volume":"12","author":"S Guedan","year":"2019","unstructured":"Guedan S, Calderon H, Posey A, et al. Engineering and Design of Chimeric Antigen Receptors. Mol Ther Methods Clin Dev. 2019;12:145\u201356.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2151_CR20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.pep.2012.02.006","volume":"83","author":"W Sun","year":"2012","unstructured":"Sun W, Xie J, Lin H, et al. A combined strategy improves the solubility of aggregation-prone single-chain variable fragment antibodies. Protein Expr Purif. 2012;83:21\u20139.","journal-title":"Protein Expr Purif"},{"issue":"8","key":"2151_CR21","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1158\/2159-8290.CD-20-0242","volume":"11","author":"M Nix","year":"2021","unstructured":"Nix M, Mandal K, Geng H, et al. Surface proteomics reveals CD72 as a target for in vitro-evolved nanobody-based CAR-T cells in KMT2A\/MLL1-rearranged B-ALL. Cancer Discov. 2021;11(8):2032\u201349.","journal-title":"Cancer Discov."},{"key":"2151_CR22","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1182\/blood.2019002779","volume":"135","author":"X He","year":"2020","unstructured":"He X, Feng Z, Ma J, et al. Bispecific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia. Blood. 2020;135:713\u201323.","journal-title":"Blood"},{"key":"2151_CR23","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/s41392-021-00462-1","volume":"6","author":"F Mo","year":"2021","unstructured":"Mo F, Duan S, Jiang X, et al. Nanobody-based chimeric antigen receptor T cells designed by CRISPR\/Cas9 technology for solid tumor immunotherapy. Signal Transduct Target Ther. 2021;6:80.","journal-title":"Signal Transduct Target Ther"},{"key":"2151_CR24","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3389\/fimmu.2018.00273","volume":"9","author":"M Iezzi","year":"2018","unstructured":"Iezzi M, Policastro L, Werbajh S, et al. Single-domain antibodies and the promise of modular targeting in cancer imaging and treatment. Front Immunol. 2018;9:273.","journal-title":"Front Immunol"},{"key":"2151_CR25","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.2147\/IJN.S297631","volume":"16","author":"S Sun","year":"2021","unstructured":"Sun S, Ding Z, Yang X, et al. Nanobody: a small antibody with big implications for tumor therapeutic strategy. IInt J Nanomed. 2021;16:2337\u201356.","journal-title":"IInt J Nanomed"},{"key":"2151_CR26","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1146\/annurev-immunol-042617-053327","volume":"36","author":"J Ingram","year":"2018","unstructured":"Ingram J, Schmidt F, Ploegh H. Exploiting nanobodies\u2019 singular traits. Annu Rev Immunol. 2018;36:695\u2013715.","journal-title":"Annu Rev Immunol"},{"key":"2151_CR27","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00253-007-1142-2","volume":"77","author":"M Harmsen","year":"2007","unstructured":"Harmsen M, De Haard H. Properties, production, and applications of camelid single-domain antibody fragments. Appl Microbiol Biotechnol. 2007;77:13\u201322.","journal-title":"Appl Microbiol Biotechnol"},{"key":"2151_CR28","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","volume":"82","author":"S Muyldermans","year":"2013","unstructured":"Muyldermans S. Nanobodies: natural single-domain antibodies. Annu Rev Biochem. 2013;82:775\u201397.","journal-title":"Annu Rev Biochem"},{"key":"2151_CR29","doi-asserted-by":"publisher","first-page":"6013","DOI":"10.1039\/D0CS00718H","volume":"50","author":"Y Xiong","year":"2021","unstructured":"Xiong Y, Xiao C, Li Z, et al. Engineering nanomedicine for glutathione depletion-augmented cancer therapy. Chem Soc Rev. 2021;50:6013\u201341.","journal-title":"Chem Soc Rev"},{"key":"2151_CR30","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1158\/0008-5472.CAN-19-2295","volume":"80","author":"I Nessler","year":"2020","unstructured":"Nessler I, Khera E, Vance S, et al. Increased tumor penetration of single-domain antibody-drug conjugates improves efficacy in prostate cancer models. Cancer Res. 2020;80:1268\u201378.","journal-title":"Cancer Res"},{"key":"2151_CR31","doi-asserted-by":"publisher","first-page":"987","DOI":"10.4155\/tde-2017-0071","volume":"8","author":"T Nakamura","year":"2017","unstructured":"Nakamura T, Harashima H. Integration of nano drug-delivery system with cancer immunotherapy. Ther Deliv. 2017;8:987\u20131000.","journal-title":"Ther Deliv"},{"key":"2151_CR32","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/s41568-019-0186-9","volume":"19","author":"M Goldberg","year":"2019","unstructured":"Goldberg M. Improving cancer immunotherapy through nanotechnology. Nat Rev Cancer. 2019;19:587\u2013602.","journal-title":"Nat Rev Cancer"},{"key":"2151_CR33","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/s41577-019-0269-6","volume":"20","author":"D Irvine","year":"2020","unstructured":"Irvine D, Dane E. Enhancing cancer immunotherapy with nanomedicine. Nat Rev Immunol. 2020;20:321\u201334.","journal-title":"Nat Rev Immunol"},{"key":"2151_CR34","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/s41571-019-0308-z","volume":"17","author":"J Martin","year":"2020","unstructured":"Martin J, Cabral H, Stylianopoulos T, et al. Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges. Nat Rev Clin Oncol. 2020;17:251\u201366.","journal-title":"Nat Rev Clin Oncol"},{"key":"2151_CR35","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","volume":"18","author":"R Riley","year":"2019","unstructured":"Riley R, June C, Langer R, et al. Delivery technologies for cancer immunotherapy. Nat Rev Drug Discov. 2019;18:175\u201396.","journal-title":"Nat Rev Drug Discov"},{"key":"2151_CR36","doi-asserted-by":"publisher","first-page":"e1904156","DOI":"10.1002\/adma.201904156","volume":"31","author":"P Zhang","year":"2019","unstructured":"Zhang P, Zhai Y, Cai Y, et al. Nanomedicine-based immunotherapy for the treatment of cancer metastasis. Adv Mater. 2019;31:e1904156.","journal-title":"Adv Mater"},{"key":"2151_CR37","doi-asserted-by":"publisher","first-page":"12320","DOI":"10.1038\/ncomms12320","volume":"7","author":"E Jacoby","year":"2016","unstructured":"Jacoby E, Nguyen S, Fountaine T, et al. CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity. Nat Commun. 2016;7:12320.","journal-title":"Nat Commun"},{"key":"2151_CR38","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","volume":"24","author":"E Orlando","year":"2018","unstructured":"Orlando E, Han X, Tribouley C, et al. Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia. Nat Med. 2018;24:1504\u20136.","journal-title":"Nat Med"},{"key":"2151_CR39","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","volume":"5","author":"E Sotillo","year":"2015","unstructured":"Sotillo E, Barrett D, Black K, et al. Convergence of acquired mutations and alternative splicing of CD19 enables resistance to CART-19 immunotherapy. Cancer Discov. 2015;5:1282\u201395.","journal-title":"Cancer Discov"},{"key":"2151_CR40","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1038\/s41591-020-1081-3","volume":"26","author":"N Shah","year":"2020","unstructured":"Shah N, Johnson B, Schneider D, et al. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat Med. 2020;26:1569\u201375.","journal-title":"Nat Med"},{"key":"2151_CR41","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","volume":"37","author":"B Choi","year":"2019","unstructured":"Choi B, Yu X, Castano A, et al. CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nat Biotechnol. 2019;37:1049\u201358.","journal-title":"Nat Biotechnol"},{"key":"2151_CR42","doi-asserted-by":"publisher","first-page":"2283","DOI":"10.1038\/s41467-020-16160-5","volume":"11","author":"E Zah","year":"2020","unstructured":"Zah E, Nam E, Bhuvan V, et al. Systematically optimized BCMA\/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma. Nat Commun. 2020;11:2283.","journal-title":"Nat Commun"},{"key":"2151_CR43","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1158\/2326-6066.CIR-15-0231","volume":"4","author":"E Zah","year":"2016","unstructured":"Zah E, Lin M, Silva-Benedict A, et al. T cells expressing CD19\/CD20 bispecific chimeric antigen receptors prevent antigen escape by malignant B cells. Cancer Immunol Res. 2016;4:498\u2013508.","journal-title":"Cancer Immunol Res"},{"key":"2151_CR44","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"C June","year":"2018","unstructured":"June C, O\u2019Connor R, Kawalekar O, et al. CAR T cell immunotherapy for human cancer. Science. 2018;359:1361\u20135.","journal-title":"Science"},{"key":"2151_CR45","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41571-020-0427-6","volume":"18","author":"L Mikkilineni","year":"2021","unstructured":"Mikkilineni L, Kochenderfer J. CAR T cell therapies for patients with multiple myeloma. Nat Rev Clin Oncol. 2021;18:71\u201384.","journal-title":"Nat Rev Clin Oncol"},{"key":"2151_CR46","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1016\/S1470-2045(19)30729-6","volume":"21","author":"M Elsallab","year":"2020","unstructured":"Elsallab M, Levine B, Wayne A, et al. CAR T-cell product performance in haematological malignancies before and after marketing authorisation. Lancet Oncol. 2020;21:e104\u201316.","journal-title":"Lancet Oncol"},{"key":"2151_CR47","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1200\/JCO.18.01457","volume":"37","author":"C Jacobson","year":"2019","unstructured":"Jacobson C. CD19 chimeric antigen receptor therapy for refractory aggressive B-cell lymphoma. J Clin Oncol. 2019;37:328\u201335.","journal-title":"J Clin Oncol"},{"key":"2151_CR48","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/nrclinonc.2017.128","volume":"15","author":"J Brudno","year":"2018","unstructured":"Brudno J, Kochenderfer J. Chimeric antigen receptor T-cell therapies for lymphoma. Nat Rev Clin Oncol. 2018;15:31\u201346.","journal-title":"Nat Rev Clin Oncol"},{"key":"2151_CR49","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","volume":"365","author":"D Porter","year":"2011","unstructured":"Porter D, Levine B, Kalos M, et al. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365:725\u201333.","journal-title":"N Engl J Med"},{"key":"2151_CR50","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/nrclinonc.2013.46","volume":"10","author":"J Kochenderfer","year":"2013","unstructured":"Kochenderfer J, Rosenberg S. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol. 2013;10:267\u201376.","journal-title":"Nat Rev Clin Oncol"},{"key":"2151_CR51","doi-asserted-by":"publisher","first-page":"e168","DOI":"10.1016\/S1470-2045(19)30823-X","volume":"21","author":"A Singh","year":"2020","unstructured":"Singh A, McGuirk J. CAR T cells: continuation in a revolution of immunotherapy. Lancet Oncol. 2020;21:e168\u201378.","journal-title":"Lancet Oncol"},{"key":"2151_CR52","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","volume":"38","author":"M Hong","year":"2020","unstructured":"Hong M, Clubb J, Chen Y, Engineering. CAR-T cells for next-generation cancer therapy. Cancer Cell. 2020;38:473\u201388.","journal-title":"Cancer Cell"},{"key":"2151_CR53","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1038\/s41568-020-00323-z","volume":"21","author":"R Larson","year":"2021","unstructured":"Larson R, Maus M. Recent advances and discoveries in the mechanisms and functions of CAR T cells. Nat Rev Cancer. 2021;21:145\u201361.","journal-title":"Nat Rev Cancer"},{"key":"2151_CR54","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","volume":"17","author":"S Rafiq","year":"2020","unstructured":"Rafiq S, Hackett C, Brentjens R. Engineering strategies to overcome the current roadblocks in CAR T cell therapy. Nat Rev Clin Oncol. 2020;17:147\u201367.","journal-title":"Nat Rev Clin Oncol"},{"key":"2151_CR55","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12943-019-1057-4","volume":"18","author":"S Yu","year":"2019","unstructured":"Yu S, Yi M, Qin S, et al. Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity. Mol Cancer. 2019;18:125.","journal-title":"Mol Cancer"},{"key":"2151_CR56","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3390\/biom11020238","volume":"11","author":"C Bao","year":"2021","unstructured":"Bao C, Gao Q, Li L, et al. The application of nanobody in CAR-T therapy. Biomolecules. 2021;11:238.","journal-title":"Biomolecules."},{"key":"2151_CR57","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.addr.2019.04.006","volume":"141","author":"F Rahbarizadeh","year":"2019","unstructured":"Rahbarizadeh F, Ahmadvand D, Moghimi S. CAR T-cell bioengineering: Single variable domain of heavy chain antibody targeted CARs. Adv Drug Deliv Rev. 2019;141:41\u20136.","journal-title":"Adv Drug Deliv Rev"},{"key":"2151_CR58","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41565-020-00822-y","volume":"16","author":"N Gong","year":"2021","unstructured":"Gong N, Sheppard N, Billingsley M, et al. Nanomaterials for T-cell cancer immunotherapy. Nat Nanotechnol. 2021;16:25\u201336.","journal-title":"Nat Nanotechnol"},{"key":"2151_CR59","doi-asserted-by":"publisher","first-page":"7792","DOI":"10.7150\/thno.35486","volume":"9","author":"X Yang","year":"2019","unstructured":"Yang X, Xie S, Yang X, et al. Opportunities and challenges for antibodies against intracellular antigens. Theranostics. 2019;9:7792\u2013806.","journal-title":"Theranostics"},{"key":"2151_CR60","doi-asserted-by":"publisher","first-page":"7624","DOI":"10.1073\/pnas.1817147116","volume":"116","author":"Y Xie","year":"2019","unstructured":"Xie Y, Dougan M, Jailkhani N, et al. Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice. Proc Natl Acad Sci USA. 2019;116:7624\u201331.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2151_CR61","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nm.3838","volume":"21","author":"AH Long","year":"2015","unstructured":"Long AH, Haso WM, Shern JF, et al. 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors. Nat Med. 2015;21:581\u201390.","journal-title":"Nat Med"},{"key":"2151_CR62","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00530-z","author":"KM Cappell","year":"2021","unstructured":"Cappell KM, Kochenderfer JN. A comparison of chimeric antigen receptors containing CD28 versus 4\u20131BB costimulatory domains. Nat Rev Clin Oncol. 2021. https:\/\/doi.org\/10.1038\/s41571-021-00530-z.","journal-title":"Nat Rev Clin Oncol."},{"key":"2151_CR63","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","volume":"44","author":"OU Kawalekar","year":"2016","unstructured":"Kawalekar OU, O\u2019Connor RS, Fraietta JA, et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity. 2016;44:380\u201390.","journal-title":"Immunity"},{"key":"2151_CR64","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/nature21405","volume":"543","author":"J Eyquem","year":"2017","unstructured":"Eyquem J, Mansilla-Soto J, Giavridis T, et al. Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection. Nature. 2017;543:113\u20137.","journal-title":"Nature"},{"key":"2151_CR65","doi-asserted-by":"publisher","first-page":"5515","DOI":"10.2147\/OTT.S245169","volume":"13","author":"J Jureczek","year":"2020","unstructured":"Jureczek J, Feldmann A, Bergmann R, et al. Highly efficient targeting of EGFR-expressing tumor cells with UniCAR T cells via target modules based on cetuximab. Onco Targets Ther. 2020;13:5515\u201327.","journal-title":"Onco Targets Ther"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-021-02151-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-021-02151-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-021-02151-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T23:31:54Z","timestamp":1673134314000},"score":1,"resource":{"primary":{"URL":"https:\/\/cancerci.biomedcentral.com\/articles\/10.1186\/s12935-021-02151-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,24]]},"references-count":65,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2151"],"URL":"https:\/\/doi.org\/10.1186\/s12935-021-02151-z","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,24]]},"assertion":[{"value":"20 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All studies involving human blood cells were approved by the Ethics Committee of the General Hospital of Ningxia Medical University (number: KYLL-2021-216), and consent was obtained from patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"450"}}